Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a report published on Monday,Benzinga reports. The brokerage currently has a $240.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. Citigroup reaffirmed a “neutral” rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Finally, Chardan Capital cut their price objective on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $209.00.

Get Our Latest Analysis on Krystal Biotech

Krystal Biotech Trading Down 0.2%

NASDAQ KRYS opened at $154.05 on Monday. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of 31.31 and a beta of 0.66. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $207.84. The stock has a 50-day moving average of $147.46 and a 200 day moving average of $152.30.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analysts’ expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 13,435 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 49,800 shares of company stock valued at $7,487,943 in the last 90 days. Corporate insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its holdings in Krystal Biotech by 41.4% in the second quarter. Osaic Holdings Inc. now owns 393 shares of the company’s stock valued at $54,000 after acquiring an additional 115 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in Krystal Biotech by 0.6% in the second quarter. Thrivent Financial for Lutherans now owns 18,700 shares of the company’s stock valued at $2,571,000 after acquiring an additional 110 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in Krystal Biotech by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 86,688 shares of the company’s stock valued at $11,916,000 after acquiring an additional 6,424 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Krystal Biotech by 310.7% in the second quarter. Tower Research Capital LLC TRC now owns 2,998 shares of the company’s stock valued at $412,000 after acquiring an additional 2,268 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its holdings in Krystal Biotech by 71.4% in the second quarter. E Fund Management Co. Ltd. now owns 3,870 shares of the company’s stock valued at $532,000 after acquiring an additional 1,612 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

See Also